KW-0761

BIOLOGICAL9 trials

Sponsors

Kyowa Kirin Co., Ltd., Kyowa Kirin, Inc., Pfizer

Conditions

Adult Peripheral T-Cell Lymphoma (PTCL)Adult T-Cell Leukemia and Lymphoma (ATL)Adult T-cell Leukemia-LymphomaAdult T-cell Leukemia-lymphomaAdvanced/Metastatic Solid TumorsCutaneous T-Cell LymphomaCutaneous T-cell LymphomaPeripheral T-Cell Lymphoma

Phase 1

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

CompletedNCT00355472

Kyowa Kirin Co., Ltd.Adult Peripheral T-Cell Lymphoma (PTCL), Adult T-Cell Leukemia and Lymphoma (ATL)

Start: 2007-02-28End: 2008-10-31Updated: 2012-10-18

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

CompletedNCT00888927

Kyowa Kirin Co., Ltd.Peripheral T-Cell Lymphoma

Start: 2009-05-31End: 2012-09-30Updated: 2024-04-25

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

TerminatedNCT02444793

PfizerAdvanced/Metastatic Solid Tumors

Start: 2015-05-31End: 2017-10-31Updated: 2019-02-27

Phase 2

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

CompletedNCT00920790

Kyowa Kirin Co., Ltd.Adult T-cell Leukemia-lymphoma

Start: 2009-06-30End: 2010-11-30Updated: 2017-03-29

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

CompletedNCT01173887

Kyowa Kirin Co., Ltd.Adult T-cell Leukemia-Lymphoma

Start: 2010-07-31End: 2012-04-30Updated: 2017-03-30

Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma

CompletedNCT01192984

Kyowa Kirin Co., Ltd.Peripheral T/NK-cell Lymphoma

Start: 2010-09-30End: 2012-05-31Updated: 2017-03-03

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

CompletedNCT01226472

Kyowa Kirin Co., Ltd.Cutaneous T-cell Lymphoma, Peripheral T-cell Lymphoma

Start: 2010-08-31End: 2012-09-30Updated: 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

CompletedNCT01626664

Kyowa Kirin, Inc.Adult T-cell Leukemia-Lymphoma

Start: 2012-06-30End: 2018-02-28Updated: 2024-04-25

Phase 3

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

CompletedNCT01728805

Kyowa Kirin, Inc.Cutaneous T-Cell Lymphoma

Start: 2012-11-30End: 2021-02-17Updated: 2024-04-25

Related Papers

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma

Hematological Oncology2025-06-281 citations

Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

Journal of the European Academy of Dermatology and Venereology2024-09-243 citations

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Blood2023-11-02

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome

Journal of the European Academy of Dermatology and Venereology2022-08-2219 citations

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial

Leukemia & lymphoma/Leukemia and lymphoma2021-07-2616 citations

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

Journal of the European Academy of Dermatology and Venereology2021-07-1736 citations

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Blood2020-11-048 citations

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2019-12-0157 citations

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Blood2019-11-134 citations

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Blood2019-11-133 citations

Breakthrough Therapy Designation

Oncology Times2019-07-11

Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.

Journal of Clinical Oncology2019-05-209 citations

Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study.

Journal of Clinical Oncology2019-05-20

Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study

Blood2018-11-294 citations

Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL)

Blood2018-11-292 citations

Mogamulizumab Demonstrates Efficacy Against Cutaneous T-Cell Lymphoma

Oncology Times2018-11-14

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

2018-08-09454 citations

Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial.

Journal of Clinical Oncology2018-05-204 citations

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

Blood2017-12-0717 citations

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and <scp>II</scp> studies

Cancer Science2017-08-0465 citations

8 more papers not shown